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18F-Methylcholine (FCH) is a marker of proliferation that
can be used for the detection and (re)staging of prostate
cancer [1, 2]. A 78-year-old male with T3G3 prostate
cancer (PSA 47 μg/l, nadir PSA 2.2 μg/l with LHRH
treatment) and rising PSA (4.8 μg/l) was referred for
restaging with FCH PET/CT. Images obtained 30 minutes
after injection (a, b) demonstrated choline-avid nodal
metastases in the left parailiac and paraaortal regions (blue
arrowheads). In addition, the upper lobe of the right lung
showed diffuse FCH uptake with SUVmean 3.0 (red arrow-
heads) and diffuse infiltration on low-dose CT (c). Several
enlarged mediastinal lymph nodes showed uptake as well
(green arrowheads). Pulmonary infection with reactive
nodes was suspected, but we were unable to discriminate
them from mediastinal prostate cancer metastases.
In retrospect, the patient had been coughing for several
weeks but had no other symptoms. Bronchial lavage
revealed legionellosis. After 3 weeks treatment with
ciprofloxacin the pulmonary infiltration had disappeared
completely on the CT scan (d), confirming the inflamma-
tory origin of the choline uptake. However, the enlarged
mediastinal lymph nodes persisted. No further investiga-
tions of the mediastinum were performed because of the
age and prognosis of the patient, and the origin of the
enlarged nodes remained uncertain.
As previously suggested by animal experiments [3],
active infection can be choline-avid. Our case demonstrates
that this can even occur in a diffuse and clinically indolent
infection. We conclude that, as in FDG PET imaging, when
active infection is suspected, adequate antimicrobial treat-
ment should precede FCH PET/CT to avoid compromised
imaging of oncological disease.
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